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Lipoprotein heterogeneity in end-stage renal failure. Fifteen patients
on chronic maintenance hemodialysis without any additional known
cause for dyslipidemia were arbitrarily divided into two groups based
on fasting plasma triglyceride levels. The hypertriglyceridemic patients
(plasma triglyceride levels above 170 mg/dl, N = 7) also had decreased
high density lipoprotein (HDL) cholesterol levels and decreased post-
heparin plasma lipoprotein lipase activity compared to the normotri-
glyceridemic patients (N = 8). All lipoprotein fractions collected by
density gradient ultracentrifugation were triglyceride-enriched in the
hypertriglyceridemic patients. Both groups of patients had elevated
intermediate density lipoprotein levels, heterogeneity in the distribution
of low density lipoproteins (LDL) and apoprotein-specific HDL sub-
populations, and abnormalities in the size and composition of both LDL
and HDL. The described alterations tended to be more marked in
hypertriglyceridemic patients and are not detected by the usual labora-
tory evaluation of lipoproteins. These lipoprotein abnormalities have
been shown to be atherogenic in patients without renal disease and are
likely to contribute to the high prevalence of premature atherosclerosis
in end-stage renal disease.
The major cause of death among patients with chronic renal
failure is atherosclerotic cardiovascular disease in which nu-
merous predisposing factors, mainly hypertension and lipid
abnormalities, are frequently observed [1—3]. There is a well-
known epidemiological association between coronary heart
disease and increased levels of low density lipoprotein (LDL)
cholesterol and (or) decreased levels of high density lipoprotein
(HDL) cholesterol [4, 5]. As a group, uremic patients undergo-
ing hemodialysis, in whom other concomitant causes of dyslip-
idemia have been excluded, show high plasma triglyceride and
low-to-normal LDL cholesterol levels and decreased HDL
cholesterol levels [6—12]. Such a pattern has been ascribed to
disturbances in the key enzymes, mainly lipoprotein lipase
(LPL) and hepatic lipase (HL), that govern normal lipoprotein
metabolism [13—151.
Thus, the lipoprotein abnormalities associated with the se-
vere atherosclerosis of these patients are increased triglyceride-
rich lipoproteins, decreased HDL, or both. Although much
effort has been devoted to the study of LPL catalytic activity in
these patients [13—18], the LPL enzyme mass has not been
quantitated to differentiate between a decrease in enzyme
protein or the presence of catalytically defective protein. Since
little is known about changes in lipoprotein remnants or inter-
mediate density lipoproteins (IDL) in renal failure [9], informa-
tion about these particles may be especially important in view
of their postulated atherogenicity [19].
The aim of this study was to further elucidate the role of the
triglyceride lipase function in a model of partial LPL and HL
deficiency and to determine the lipoprotein structural abnormal-
ities observed in these patients.
Methods
Study subjects
Fifteen patients, from the Scribner Kidney Center (Seattle,
Washington, USA), with end-stage renal failure on maintenance
hemodialysis for 12 to 156 months in a three times a week
treatment for three to four hours, were selected from 73
available patients. All patients were dialyzed against a bicar-
bonate bath. There were 11 women and four men in the group.
Underlying renal diseases were: chronic glomerulonephritis (N
= 7), polycystic kidney disease (N = 3), obstructive uropathy
(N 3), interstitial nephritis (N = 1) and genetic abnormalities
of the urinary tract (N 1). Patients received no medication
except erythropoietin, multivitamins, calcium carbonate, alu-
minum hydroxide, and/or iron. Patients on erythropoietin for
more than nine months were felt to be metabolically stable and
were included (N = 7). Fifty-eight patients were sequentially
excluded for: being over the age of 65 years (N = 6), the
presence of primary hyperlipidemias (N = 2), a body mass
index (BMI) of over 31 kg/m2(N 1), a BMI of under 17kg/rn2
(N = 3), the presence of diabetes mellitus (N 10), the intake
of beta-blockers, androgens or any drug affecting lipid metab-
olism (N = 6), being on erythropoietin for less than nine months
(N = 21), the concurrence of liver disease (N = 1), cardiovas-
cular disease (N = 2), or lupus erythematosus (N 2). During
the course of the study, one patient died and one received an
allograft kidney transplant, while two refused to participate in
the study. For comparison, suitable healthy controls not taking
hormones or drugs known to affect plasma lipid levels and with
similar age and gender distribution were included when neces-
sary.
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Blood samples
Blood was drawn from all patients after an overnight fast
immediately before a dialysis and at least 42 hours after the last
dialysis. Prior to the administration of heparin, blood was
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drawn into tubes containing either EDTA or lithium heparin.
All patients were within 2% of their fluid free weight which was
used to calculate the heparin doses (60 U/kg). Ten minutes after
the injection of heparin, another blood sample was obtained
into a tube containing lithium heparin. Plasma was separated
without delay by centrifugation at 4°C and immediately pro-
cessed or stored at —70°C without subsequent thawing until the
assay.
Discontinuous gradient ultracentrfugation
The overall lipoprotein profile was obtained by a modification
of the single vertical discontinuous density gradient ultracen-
trifugation as described by Chung et a! [201. The separation was
accomplished in a Beckman L8-70 ultracentrifuge with a
TV865B rotor (65,000 rpm, 90 mm, 5°C). Plasma density was
adjusted to 1.08 g/ml with a KBr solution of d = 1.21 g/mI to a
final volume of 5 ml and underlayered on 12 ml of normal saline
(d = 1.006 g/ml). After centrifugation, 38 fractions were col-
lected puncturing the bottom of each tube, for determination of
cholesterol and triglyceride by the respective enzymatic assay
method using Boehringer Mannheim (Marburg, Germany) re-
agents.
Nondenaturing gradient gel electrophoresis
Four microliters from each sample were applied to alternate
wells on 2% to 16% polyacrylamide gradient gels (Pharmacia,
Uppsala, Sweden) and electrophoresed as described [21]. Latex
beads (Duke Scientific, Palo Alto, California, USA), thyroglob-
ulin, and ferritin (Pharmacia) with diameters of 38.0, 17.0 and
12.2 nm respectively, were run as standards. The diameter of
LDL bands were determined by using a calibration curve
generated from the standards.
Lipoprotein fractionation
Two aliquots of the plasma were subjected to preparative
ultracentrifugation to separate VLDL (d  1.006 g/ml) and
VLDL plus IDL (d 1.019 g/ml) by sequential ultracentrifuga-
tion [221 using tube-slicing to quantitatively isolate the frac-
tions. Cholesterol and triglyceride were performed on each
fraction, and the difference between the d  1.019 glml and d 
1.006 g/ml fractions was considered as IDL cholesterol and
triglyceride. HDL was obtained by precipitation according to
the Lipid Research Clinics Program [23]. LDL cholesterol and
triglyceride were calculated by subtracting from total plasma
cholesterol and triglyceride the respective values for VLDL,
IDL and HDL. For determination of HDL2 and HDL3 choles-
terol a sequential precipitation procedure was used as described
[241.
Measurement of plasma lipoprotein lipase activity and mass
and hepatic triglyceride lipase activity
LPL activity was measured in post-heparin plasma while
LPL mass was measured in both pre- and postheparin plasma
samples. LPL and HL activities were measured as previously
described [25]. Postheparin plasma was incubated with the
substrate containing trio!eylglycero!, g!ycerol-tri-(1-14C)-oleate
emulsified with phosphatidyl choline for 60 minutes at 37°C, and
the liberated fatty acids were extracted and counted. LPL was
selectively blocked by the monoclonal antibody 5D2 prepared
as reported previously [26] and LPL activity was calculated as
the lipolytic activity (expressed in nmol of free fatty acids
released per mm per ml of plasma) removed by the addition of
the antibody, while the HL activity was that remaining. Interas-
say variation was corrected by the addition of adequate stan-
dards to each assay. An enzyme-linked immunoassay for li-
poprotein lipase mass was utilized [26]. Briefly, the 5D2
antibody was incubated in microtiter plates at 37°C for four
hours. Samples and purified bovine LPL standards were diluted
and mixed with pooled human plasma and dispensed into the
wells in octuplicate. Once rinsed, the 5D2 antibody, conjugated
with horseradish peroxidase and diluted 1:10,000 with 0.25%
Tween 20 (vol/vol) in PBS, was added to the wells and incu-
bated at room temperature for three hours. Finally, peroxidase
activity was measured as absorbance at 492 nm and LPL mass
calculated from the standard curve. The incremental LPL mass
released into the plasma after heparin administration was cal-
culated by subtracting pre-heparin from post-heparin plasma
immunoreactivity.
Apoprotein A-I-containing particles isolated by
immunoaffinity chromatography
Fresh plasma samples which had been subjected to chroma-
tography on dextran sulphate cellulose to remove apo B-con-
taining particles were used for the isolation of apo A-I-contain-
ing lipoproteins with or without apo A-Il as previously
described [27]. Plasma from each subject was first incubated
with anti-All immunosorbent for one hour at 4°C to remove
particles containing both A-I and A-Il [Lp(AI w All)]. The
nonadsorbed proteins were then similarly incubated with anti
A-I immunosorbent to isolate particles containing A-I but no
A-TI [Lp(AI w/o All)]. Lipoproteins bound to anti-A-IT and
anti-A-I immunosorbents were eluted with 3 M NaSCN, imme-
diately desalted with a Sephadex G-25 column and concentrated
for subsequent analyses. The size subspecies of the two types
of apo A-I containing lipoproteins were separated by nondena-
turing gradient polyacrylamide gel electrophoresis using precast
4 to 30% gradient gels (Pharmacia) [28]. Particle size and
percent distribution of the various subspecies were calculated
as previously described [29] using the LKB 2400 Gel scan
XLTM software.
Other laboratory procedures
Apoproteins Al, All, B and E were analyzed by respective
immunoas says previously published [30—33]. The electro-
phoretic mobility of lipoprotein particles was assessed by
agarose gel electrophoresis followed by lipid staining with
Sudan Red 7BV using the ParagonTM Lipo Gel system (Beck-
man); this was performed on isolated VLDL and on the bottom
fraction with d  1.006 g!ml. Apo E pattern was determined by
isoelectrofocusing of delipidated VLDL particles on 7.5% poly-
acrylamide gel containing 8 M urea and pH 4 to 6 ampholytes
[341.
Statistical analyses
Data were initially analyzed employing Snedecor's F-test of
homogeneity of variances. Differences between groups were
then assessed using two sample non-pooled t-test (parametric)
412 Joven et al: Lipoprotein heterogeneity in ESRD
Table 1. Sex, age, months on dialysis, blood pressure and biometric data
Patient
number Sex
Age
years
Months
on dialysis
Blood pressure mm Hg
Weight
kg
Height
cm
BMI
kg/rn2
Triceps
skinfold
mmsystolic dyastolic
Hypertriglyceridemica
1 F 52 148 125 75 56 166 20.3 14
2 M 26 59 122 78 86 180 26.5 14
3 F 52 95 130 80 65 165 23.9 12
4 F 24 60 102 64 49 158 19.7 10
5 F 48 55 108 70 61 141 30.5 21
6 M 43 26 130 65 76 188 21.7 11
7 F 58 117 140 50 65 169 22.9 21
Mean 43.3 80.0 122.4 68.9 65.4 166.7 23.6 14.7
SD 13.3 42.0 13.3 10.3 12.3 15.1 3.8 4.5
Normotriglyceridemic
S F 50 12 164 96 58 161 22.6 10
9 F 52 47 160 98 56 154 23.6 26
10 F 41 105 100 60 62 162 23.7 22
11 M 47 120 115 70 88 187 21.7 11
12 F 40 156 100 70 57 171 19.5 17
13 F 62 140 140 70 52 171 17.8 5
14 F 59 66 110 69 67 166 24.3 16
15 M 64 27 160 89 56 174 17.5 5
Mean 51.9 84.1 131.1 77.7 62.0 168.2 21.4 14.0
SD 9.2 53.7 27.9 14.3 11.4 10.0 2.7 7.6
All patients
Mean 47.9 82.2 127.1 73.6 63.7 167.7 22.6 14.1
SD 11.7 46.9 22.1 13.1 11.6 12.1 3.4 6.4
a Plasma triglyceride concentration above 170 mg/dl
or Mann-Whitney U test (non-parametric) following the indica-
tions of the F-test. Levels of P  0.05 were taken as significant.
The Pearson product moment correlation coefficients were used
to evaluate the degree of linear relationship between measured
variables. The ellipsoid that describes the 78% confidence
interval of LPL activity and mass for the controls was calcu-
lated from the mean and variance of the enzyme activity and the
mass plus the covariance between them in a group of healthy
controls, as described [26].
Results
The patients were arbitrarily divided into two subgroups of
nearly equal size with plasma triglyceride concentration below
(N = 8) or above (N 7)170 mg/dl, and this distribution was
maintained for all analyses. There were no significant differ-
ences between the two groups with respect to sex, age, months
on dialysis, blood pressure and biometric data (Table 1),
although hypertriglyceridemic patients were somewhat younger
and had higher BMI than normotriglyceridemic patients. By
definition, hypertriglyceridemic patients showed significantly
higher plasma triglyceride levels than normotriglyceridemic
ones (Table 2). This increase was due to increases in VLDL-
triglyceride, although all the isolated subfractions showed a
relative triglyceride enrichment. Hypertriglyceridemic patients
also showed significant increases in VLDL-cholesterol and
significant decreases in HDL-cholesterol as compared to nor-
motriglyceridemic patients. Interestingly, despite such differ-
ences in the cholesterol and triglyceride distribution, both
groups had strikingly increased IDL-cholesterol concentration
as compared to controls. Mean plasma apoprotein B concen-
tration was slightly higher in hypertriglyceridemic patients than
in the controls and normotriglyceridemic patients, but the
differences did not reach statistical significance. Plasma apo-
protein A-I, A-I! and E levels were also similar to those
obtained in population controls (Table 3). Three hypertriglyc-
endemic and six normotriglyceridemic patients had sinking
pre-beta, double pre-beta, or both lipoproteins on the agarose
gel electrophoresis with an overall frequency of 60%, at least
threefold that observed in normal population [35, 36]. Although
there were no statistically significant differences between the
two groups for LPL mass, LPL activity and HL activity (Table
4, Fig. 1), dialysis patients had significantly lower LPL activity
compared to controls. The difference in LPL incremental mass
between normotriglyceridemic patients and controls did not
reach statistical significance. Eleven of 15 patients (74%) fell
outside the ellipse of normal LPL mass and activity (Fig. 1),
The significant correlation between the post-heparin plasma
LPL activity and incremental enzyme mass found in controls (r
= 0.85, N = 27, P  0.001) also was seen in patients (r = 0.94,
N = 15, P 0.001). In controls, the specific activity of the
post-heparin plasma enzyme seems to be fairly uniform (1.15
0.20 nmolJminlng, coefficient of variation = 17.4%) while in
patients a broad distribution was noted (1.12 0.67 nmol/minl
ng, coefficient of variation = 59.8%). When the four patients
with extremely low LPL mass values are excluded, the remain-
ing 11 patients had significantly lower enzyme specific activity
than the controls (0.84 0.13 vs. 1.15 0.20, P 0.001). LPL
activity tended to be lower in the hypertriglyceridemic dialysis
patients than in the normotriglycendemic patients (P = 0.09),
while there was no statistically significant differences between
the two groups for LPL mass or HL activity. The distribution of
cholesterol and triglyceride was examined along the density
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Table 2. Cholesterol and triglyceride in plasma and the isolated subfractions
Cholesterol mg/dl Triglyceride mg/dl
Plasma VLDL IDL LDL2 HDL HDL2 HDL3 Plasma VLDL IDL LDL2 HDL
Hypertriglyceridemic
1 312 75 78 124 36 6 30 293 169 50 58 16
2 189 43 27 88 31 5 26 199 157 11 16 14
3 214 57 32 95 30 7 23 251 172 26 34 20
4 173 64 23 47 39 4 35 284 216 23 15 30
5 228 53 35 98 42 9 33 203 138 21 26 18
6 179 55 19 70 35 5 30 227 183 10 20 14
7 236 122 27 58 29 3 26 563 503 18 26 15
Mean 218.7 670b 344C 82.8 34.6a 5.6 29.Oa 2886b 219.7a 22.7 27.9a 18.la
SD 47.7 26.7 19.9 26.3 4.9 1.9 4.2 126.4 127.2 13.4 14.8 5.7
Normotriglycendemic
8 273 35 43 154 41 7 34 167 110 6 36 13
9 236 17 44 130 44 8 36 128 69 29 19 11
10 122 20 27 40 34 4 30 89 52 9 17 11
11 151 18 25 67 41 8 33 102 61 18 9 14
12 192 20 44 84 44 7 37 113 60 24 18 11
13 136 14 10 72 40 6 34 72 39 12 12 9
14 194 27 31 76 60 22 38 145 96 13 17 19
15 178 10 1 109 58 21 37 43 12 3 21 7
Mean 185.3 20.1 28.lc 91.5 45.2 10.4 34.9 107.4 62.4 14.6 18.6 11.9
SD 50.8 7.8 16.1 37.1 9.1 6.9 2.6 40.0 30.8 8.6 8.0 3.6
All patients
Mean 200.9 42.0 3l.lc 87.5 40.3 8.2 32.0 191.9 135.6 18.4 22.9 14.8
SD 50.6 30.2 17.6 31.7 9.1 5.6 4.8 128.1 118.4 11.5 12.2 5.5
Controls (N = 26)
Mean 192.5 14.9 6.4 117.6 53.6 16.1 37.5 90.1 64.1 7.2 11.6 7.2
SD 41.7 6.6 5.1 19.3 15.5 4.2 2.7 43.1 14.5 5.1 5.2 5.9
a j 0.05 and b 0.01 with respect to normotriglyceridemic
P 0.01 patients with respect to controls (21 females and 5 males, aged 28—50 years with plasma cholesterol and triglyceride concentration
within the 25th—75th percentile of the Lipid Research Clinic Prevalence Study Population)
gradient formed during the vertical rotor ultracentrifugation
(Fig. 2). The hypertriglyceridemic patients showed a broader
apparent LDL peak and a relative enrichment in triglyceride
more notorious in VLDL and IDL. In the normotriglyceridemic
group there was not a triglyceride enrichment in the HDL
fractions as compared to the control profile.
Densitometric scans of electrophoresed plasma in 2 to 16%
gradient gels showed great variation in the number of observed
peaks, in the Stokes diameter of the different particles, and in
the relative magnitudes of the areas associated with the peaks.
The occurrence of peaks at specific Stokes diameters (Fig. 3)
demonstrates their apparent heterogeneity, with an increased
number of peaks not seen in normal controls. Likewise, in-
creased heterogeneity was also observed in apo A-I containing
particles isolated by immunoaffinity-chromatography (Fig. 4).
As previously described [27, 29, 37], the size distribution of
[Lp(AI w/o All)] is clearly bimodal in healthy, normolipidemic
subjects. This distribution is completely altered in all the
patients studied (Fig. 4). Most noticeably, the relative propor-
tions of particles with Stokes diameter in the 7.0 to 8.2 nm
region was significantly higher while those in the 9.2 to 11.2 nm
interval were significantly lower (Table 5). Similar abnormali-
ties were observed in Lp(AI w All) but to a lesser extent.
Furthermore, in Lp(AI w/o All) but not in Lp(AI w All), there
were more very small particles, with Stokes diameter less than
7 nm, which are not usually seen in controls (Fig. 4). Such
altered HDL particle size profiles were observed in both
hypertriglyceridemic and normotriglyceridemic patients and
were accompanied by changes in lipid composition. In hyper-
triglyceridemic patients, both particles contained less esterified
cholesterol, free cholesterol and phospholipid, but more tri-
glyceride respect to age- and sex-matched controls (Table 6). A
similar trend was observed in normotriglyceridemic patients
although less evident. The distribution of A-I between the two
apo-specific HDL subpopulations was also different between
patients and controls. In the patients, a greater proportion of Al
was not associated with All (42 5% vs. 36 6%, P < 0.001).
Discussion
After resolution of the technical problems related to dialysis
the survival of these patients has been highly dependent on the
absence or presence of cardiovascular heart disease, thought to
be due, in part, to lipoprotein disturbances. The most common
lipid abnormality present in patients with chronic renal failure
undergoing hemodialysis is hypertriglyceridemia which is
present in 35 to 65% of patients [6—12]. The degree of hyper-
triglyceridemia is mild to moderate in these patients, but
because of the presence of other associated lipoprotein abnor-
malities, this may be associated with a higher coronary risk than
the same hypertriglyceridemia in an otherwise healthy popula-
tion [38], although the issue is far from being completely
elucidated.
The accumulation of atherogenic remnants derived from the
catabolism of triglyceride-rich lipoproteins has been proposed
as an additional characteristic of the dyslipoproteinemia present
in uremic patients [9, 39]. We have been able to confirm that the
concentration of IDL is actually increased 2- to 10-fold in
uremic plasma in all patients except one. The elevation of IDL
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Patient Al
Apoprote
All
in mg/dl
B E
Apo E
pattern
Hypertriglyceridemic
1 110 32 193 5.2 E3/E3
2 103 25 130 3.5 E3/E2
3 109 28 159 4.1 E4/E3
4 163 46 84 2.2 E3/E3
5 132 32 106 4.2 E4/E3
6 116 28 90 1.9 E3/E3
7 115 30 129 2.7 E4/E4
Mean 121.1 31.6 127.3 3.4
sn 20.5 6.8 38.8 1.3
Normotriglyceridernic
8 128 31 151 5.4 E4/E3
9 107 34 122 4.2 E4/E3
10 106 28 73 2.3 E3/E2
11 116 34 95 2.8 E31E3
12 134 34 79 3.1 E31E2
13 128 34 85 3.5 E31E3
14 148 32 86 9.2 E3/E3
15 147 25 92 4.5 E31E3
Mean 126.8 31.5 97.9 4.4
SD 16.3 3.4 25.9 2.3
All patients
Mean 124.1 31.4 111.6 3.9
SD 17.9 5.1 34.9 1.8
Male controlsa
Mean 120.0 33.5 107.1
SD 20.1 5.1 25.9
Female controlsa
Mean 130.3 34.3 100.2
SD 22.2 5.0 26.0
Male and femalea
controls
Mean 4.6
1.6
was present irrespective of other lipid parameters and was not
due to type III hyperlipoproteinemia [40] or diabetes mellitus
[41] which have been associated with increased IDL levels.
Since the changes in lipid composition may affect the distribu-
tion of these particles in conventional ultracentrifugation, data
obtained by fractionation at predefined density ranges must be
cautiously interpreted. To detect the presence of remnant
lipoproteins we have combined gradient gel electrophoresis and
the single vertical spin ultracentrifugation to characterize the
distribution of the lipoproteins along a density gradient and a
particle size gradient. With this methodology, we also con-
firmed the presence of abnormally abundant material in the IDL
region found in fractions 17 to 29 (Fig. 2). In contrast to data
obtained with preparative ultracentrifugation (Table 2), a sig-
nificant difference can be observed in the cholesterol and
triglyceride distribution in IDL between hyper- and normotrig-
lyceridemic patients. The frequency of observed peaks by
gradient gel electrophoresis in the region of large VLDL rem-
nants (Stokes diameter higher than 36 nm) was higher in
patients with hypertriglyceridemia although both groups of
patients showed a striking heterogeneity in the number and the
particle size of the remnant subpopulations respect to controls.
Several peaks can be found in the LDL region (Fig. 3).
Compared to controls, uremic patients showed a striking het-
LPL
LPL LPL specific HL
incremental activity activity activity
mass nmol/ nmol/ nmol/
Patient ng/ml minim! ml/ng minim!
Hypertriglyceridemic
1 265 183 0.69 38
2 165 134 0.81 362
3 78 79 1.01 85
4 26 36 1.38 28
5 210 151 0.72 59
6 30 26 0.87 153
7 12 38 3.17 149
Mean 112.3a 92.4c 1.23 132.0
SD 100.9 63.4 0.90 111.0
Normotriglyceridemic
8 186 184 0.99 138
9 207 148 0.71 95
10 151 103 0.68 55
11 108 79 0.73 67
12 248 238 0.96 176
13 26 53 2.04 128
14 184 172 0.93 45
15 235 240 1.02 96
Mean 168.1 l52.la 101b 100.0
SD 72.7 69.8 0.47 45.0
All patients
Mean 142.1 124.3C 1.12 114.9
SD 88.6 71.5 0.67 81.0
Controls (N = 34)
Mean 195.7 219.8 1.15 121.7
SD 58.7 58.7 0.20 51.3
a ps 0.05, b p  0.01 and C P 0.001 vs. controls by Mann
-Whitney
100 200 300 400
erogeneity in the LDL region with multiple identifiable LDL
bands between 22 and 28 nm.
The combination of data obtained by the different techniques
suggests the presence of elevated Lp(a) levels in these patients,
but they were not directly measured. The general triglyceride
Table 3. Plasma apoproteins and apoprotein F pattern Table 4. Hepatic lipase activity and lipoprotein lipase incremental
mass, activity and specific activity in post-heparin plasma
a Population controls based on references 30—33]
U test
0
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>
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Mass, ng/ml
Fig. 1. Post-heparin plasma lipoprotein lipase (LPL) activity and
incremental mass in patients with chronic renal failure undergoing
hemodialysis (I) compared to the 78% confidence limits for LPL
activity and mass indicated by the ellipsoid dashed line.
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Fraction number
Fig. 2. Whole plasma lipoprotein cholesterol (A) and triglyceride (B)
profile by single vertical spin for hypertriglyceridemic (A) and normo-
triglyceridemic (•) patients. Each point represents the mean value
obtained for the respective group. A female control profile, HDL
cholesterol plasma concentration 62.6 mg/dl (U) is drawn for compari-
son; in controls, HDL is found in fractions Ito 7, LDL in 8 to 16, IDL
in 17 to 29 and VLDL in 30 to 38.
uremic and control females while they found significant differ-
ences with respect to controls in their uremic male subjects.
High density lipoproteins are also related to the triglyceride
transport in plasma, and are an indicator for a state of lipid
transport that protects against atherosclerosis [5]. Subnormal
values for HDL-, HDL2- and HDL3-cholesterol were noted.
The decrease in HDL cholesterol was accompanied by an
increase in HDL triglyceride with no significant decrease in apo
A-I and A-Il concentration as noted previously [6, 11]. This
implies that the plasma of uremic patients did not have a
reduced number of HDL particles. When these HDL particles
__________________________________________
were separated into two apo Al-containing subpopulations on
the basis of the presence or absence of apo A-IT, they were
found to be depleted in cholesterol and phospholipid and
enriched in triglyceride. This altered composition was present
in all patients but tended to be more marked in hypertriglycer-
idemic patients. These data are similar to those reported in
pediatric patients under continuous ambulatory peritoneal dial-
ysis [46]. When HDL particles with and without apo A-Il were
further separated into size subspecies by non-denaturing gradi-
ent polyacrylamide gel electrophoresis, the Lp(AI w/o All) of
normo- and hyper-triglyceridemic patients was extremely het-
erogeneous with respect to the controls. There was a significant
________ decrease in particles with Stokes diameters between 9.2 and
11.2 nm which is the size region corresponding to HDL2. In
normal controls, no more than 20% of Lp(AI w/o All) have
Stokes diameter between 7 and 8 nm, but small particles within
this size region were predominant in these patients. Similar
abnormalities in HDL particle sizes were also found in subjects
with coronary artery disease [47]. The precise mechanism
resulting in the accumulation of small Lp(AI w/o All) is not
clear. The increased triglyceride content and the small particle
size found in uremic patients were similar to the nascent Lp(AI
w/o All) obtained in HepG2 conditioned medium [32]. The
increased incidence of these particles in dialysis patients may
therefore reflect impaired intravascular modulation of nascent
HDL.
A significant amount of particles with Stokes diameter of less
than 7 nm were detected in dialysis patients. This was also the
case with Lp(AI w/o All) secreted by HepG2 [32]. Only trace
quantities of such materials are usually observed in normolipi-
demic non-uremic controls. These particles could represent the
so-called "free" apo A-I, which have been reported in dialysis
patients [48].
Little is known about the site of catabolism of HDL in
humans, but in rats it has been demonstrated that the kidney is
the major site of breakdown of apo A-I [49]. One might
speculate that the lack of a functioning kidney might result in
HDL particles with abnormal chemical composition and molec-
ular sizes. These structural abnormalities might account for the
decreased rate of cholesterol transfer from HDL to VLDL and
LDL as well as the impaired tissue cholesterol removal by HDL
that have been reported in these patients [50, 511. An increase
in the lipid transfer protein activity in these patients might also
explain some of the changes described.
In conclusion, the quantitative and qualitative lipoprotein
disturbances described here demonstrate a profound alteration
of the normal lipoprotein metabolism in patients with end-stage
renal failure. These abnormalities are not detected by the usual
laboratory evaluation of lipoproteins. Since many of these
enrichment of all lipoproteins (Table 2) as well as the accumu-
lation of a series of lipoproteins which are intermediate between
VLDL and LDL is consistent with a primary disorder in
VLDL. The role of LPL in the initial catabolism of triglyceride-
rich lipoproteins is well known. The function of HL remains
unclear, although it seems involved in the removal of triglycer-
ide and phospholipid from lipoproteins leading to conversion of
IDL to LDL [42, 43] and in the catabolism of HDL [29]. Our
patients generally had either low LPL activity and mass or low
specific activity as compared to controls (Fig. 1). In patients
with low LPL activity and mass a cellular defect in protein
synthesis or release seems likely. However, most patients
showed lower LPL activity for a given mass than controls
which is consistent with a defect in post-translational modifica-
tion of the enzyme or with the presence of an hypothetical
circulating inhibitor. Hepatic lipase activity in these patients
was in the normal range for age and sex. The discrepancy with
other studies [14, 16, 44] might be ascribed to differences in the
methodology employed or that previous authors either studied
only male subjects or did not make a distinction between results
obtained from male and those from female patients [14, 44].
Considering that 73% of the patients in the present study were
female, our data are in agreement with those of Crawford,
Savdie and Stewart [45] who reported similar HL activity in
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Fig. 3. Densitometric scans of ident(fiable
gradient gel electrophoretic peaks between 22
and 40 nm from the plasma of the fifteen
patients (1—15), and a control (C). LDL bands
are identifiable between 22 and 28 nm, IDL
size range between 29 and 36 nm and Lp(a)
24 17 contributes to scanned peaks of approximately
30 nm. Particles with a diameter higher than
36 nm are considered large VLDL remnants.
Fig. 4. Densitometric scans of the non-
denaturing gradient polyac,ylamide gel
electrophoresis of Lp(AI w All) ( ) and
Lp(AI w/o Al!) (—) isolated from the fifteen
patients (1—15) and from a healthy,
normolipidemic female subject (C). Indicated
on the bottom scale are positions
corresponding to 7, 8.2, 9.2, 11.2 and 17 nm.
abnormalities have been reported to be atherogenic in other
clinical circumstances, they also might influence the evolution
of coronary heart disease in patients with end-stage renal
disease.
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Table 5. Normalized densitometric scan areas measured within the indicated particle size intervals and expressed as percentage of total area
between 7.0 and 17.0 nm
Particle size
nm 11.2—17.0 9.2—11.2 8.2—9.2 7.0—8.2
Lp (AT w All)
Hypertriglyceridemic (N = 7) 5.7 1.7 23.4 6.2 48.3 6.6 22.6 62b
Normotriglyceridemic (N = 8) 5.1 1.5 24.9 7.1 48.2 6.4 21.8 31b
All patients (N = 15) 5.3 1.5 24.2 6.7a 48.3 6.5 22.2 4.6C
Controls (N = 22)" 6.2 1.7 28.9 6.0 49.0 5.4 15.9 4.6
Lp (Al w/o All)
Hypertriglyceridemic (N = 7) 10.3 2.2 20.8 73C 31.6 5.1 37.3 6.4C
Normotriglyceridemic (N = 8) 9.2 2.4 26.9 ll.5I 31.3 8.2 32.6 8.9'
All patients (N = 15) 9.7 2.3 24.0 lO.1c 31.4 6.6 34.9 7,7C
Controls (N = 22)d 11.9 3.9 38.9 7.6 32.5 6.2 16.7 5.2
a p 0.05, b P 0.01 and " P 0.001 vs. controls by Mann-Whitney U test
"Controls include 22 age- and sex-matched healthy normolipidemic subjects (6 male, 16 female age: 43 17 years) with HDL cholesterol
concentration within the 25th—75th percentile of the Lipid Research Clinic Prevalence Study Population.
Table 6. Lipid composition of the isolated high-density lipoprotein subpopulations
Esterified cholesterol Free cholesterol Triglyceride Phospholipid
mg/dl % mg/dl mgldl % mg/dl %
Lp (Al w All)
Hypertriglyceridemic 19.3 23b,e 22.6 2.7a,c 4.2 0.8a,e 4.8 o.sa.a 12.4 5.lae 14.0 43ta 50.8 9.4" 58.5(N = 7)
Normotriglyceridemic 24.0 2.4 25.6 1.1 5.4 1.2' 5.7 1.OC 6.9 2.0' 75 2.4" 57.6 6.3 61.2 1.5C(N=8)
Controls (N = 22) 26.6 3.9 24.7 2.9 7.3 2.4 6.6 1.7 5.4 2.4 4.9 2.3 70.0 16.6 63.7 3.1
Lp (Al w/o All)
Hypertriglyceridemic 9.4 1.7e 21.7 2.2ac 1.7 0.6 3.7 0.9w 6.7 1.se 15.7 4,1b,e 25.6 5.0" 58.8 2.7C(N=7)
Normotriglyceridemic 12.9 4.8 24.4 1.3 2.9 2.0C 5.1 19d 4.9 2.4 9.6 3.6" 32.1 11.8 60.9 2.0(N=8)
Controls (N = 22)f 13.9 4.0 23.9 3.3 4.1 1.4 7.1 1.0 3.6 1.4 6.2 1.9 36.5 12.6 62.8 3.8
a P 0.05 and b p 0.01 vs. normotriglycendemic by Mann-Whitney U test
° J  0.05, "P 0.01 and P  0.001 with respect to controls by Mann-Whitney U test
Controls: see Table 5
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